Meeting
2023 ASCO Annual Meeting
The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.
Authors
Petros Christopoulos
Department of Thoracic Oncology, Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
Petros Christopoulos , Miriam Blasi , Dirk Eberhard , Daniel Kazdal , Teresa Romero Cruz , Farastuk Bozorgmehr , Rajiv Shah , Florian Eichhorn , Hauke Winter , Jonas Kuon , Jan Budczies , Helge Bischoff , Albrecht Stenzinger , Michael Thomas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9090)
DOI
10.1200/JCO.2023.41.16_suppl.9090
Abstract #
9090
Poster Bd #
78
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
First Author: Biagio Ricciuti
Poster
2023 ASCO Annual Meeting
Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes.
First Author: Hina Khan
Poster
2023 ASCO Annual Meeting
Updated molecular analysis of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC).
First Author: Jennifer Aline Marks
Poster
2023 ASCO Annual Meeting
A phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation.
First Author: Colin R Lindsay